Compare Lamb Weston Holdings Inc (LW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Sana Biotechnology Inc — how do they compare? Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Lamb Weston Holdings Inc is far larger — about 8.1× Sana Biotechnology Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Sana Biotechnology Inc for 23 Days on average.
| LW | SANA | |
|---|---|---|
Market Cap | $6.81B | $836.71M |
Volume | 4,638,686 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $5.92 |
52-Week Low | $38.48 | $2.68 |
Typical Hold Time | 66 Days | 23 Days |
Enterprise Value | $10.61B | $749.96M |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $49.46, up 2.85% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 27.03. Recent news highlights cost-saving initiatives and anticipation for Q1 2026 earnings, while analyst consensus leans toward a hold with a $53.71 price target, suggesting modest upside from current levels.
Outlook remains cautiously optimistic given earnings momentum and operational improvements, but risks include margin pressure from rising costs and competitive threats. The stock's valuation appears fair relative to peers, with potential for growth if margin recovery continues, though investor confidence hinges on upcoming earnings results and execution of strategic initiatives.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
